AJCN Tufts Nutrition Symposium, Boston Sept 24-26
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by ROGINSKY, M. S.
Right arrow Articles by BARNETT, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by ROGINSKY, M. S.
Right arrow Articles by BARNETT, J.
Agricola
Right arrow Articles by ROGINSKY, M. S.
Right arrow Articles by BARNETT, J.

American Journal of Clinical Nutrition, Vol 19, 223-226, Copyright © 1966 by The American Society for Clinical Nutrition, Inc.

Double-Blind Study of Phenethyldiguanide in Weight Control of Obese Nondiabetic Subjects

MARTIN S. ROGINSKY M.D.1 and JACQUELINE BARNETT B.S.1

1 From the Department of Medicine, Meadowbrook Hospital, East Meadow, Long Island, New York

A double-blind study of the effectiveness of phenformin, a phenethyldiguanide, in a weight reduction program of obese subjects with normal glucose tolerance was made. After fifteen weeks of drug administration the increased loss of weight in the group given phenformin could be attributed to the great weight losses in subjects genetically predisposed to diabetes. No change in fasting blood sugar or serum cholesterol levels was observed. Side effects were negligible. The exact mode of action of the diguanides remains unknown.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1966 by The American Society for Nutrition